Navigation Links
Generex Provides Clarification of Facts
Date:6/27/2011

ected insulin such as prolonged reduction of over-production of glucose by the liver.  The press release also stated that "a consensus meeting with the FDA to obtain agreement with the clinical plan and submission data package is planned this year to insure timely regulatory agency review and positive marketing approval."

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  Antigen Express has pioneered the use of specific CD4+ T helper stimulation in immunotherapy.  One of its platform technologies relies on inhibition of expression of the Ii protein.  Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and prevents the further growth of cancer cells.  For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" w
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Generex Announces Results of Annual Stockholders Meeting
2. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
3. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
4. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
5. Generex Announces $3.0 Million Capital Investment
6. Generex Provides Additional Details for October 21st Live Video Webcast
7. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
8. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
9. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
10. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
11. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... With its latest polyacrylonitrile (PAN) ... achieve faster flow rates in comparison to nylon or polyethersulfone (PES). Its ... allow easy liquid flow while trapping particulates as small as 0.2 micron in ...
(Date:6/30/2015)... ... 30, 2015 , ... Matrix Marketing Group, LLC , a leading provider ... to head up its account management department as vice president of client services. ... senior account management and delivery expertise to the growing Matrix Marketing Group team in ...
(Date:6/30/2015)... VANCOUVER , June 30, 2015 /PRNewswire/ - ... a clinical stage regenerative medicine company focused on ... the first participant in its Phase 1/2 clinical ... of chronic unilateral Achilles tendinosis, has been enrolled ... to intra-tendon ultrasound-guided injections. RCT-01 is comprised of ...
(Date:6/30/2015)... ... June 30, 2015 , ... Smarter Alloys ... a revolutionary new archwire that allows orthodontists to simultaneously apply different forces to ... efficacy of SmartArch. “We’re thrilled about taking SmartArch one step closer to commercial ...
Breaking Biology Technology:New Nanofiber Membrane Provides Fast, Efficient Filtration 2Matrix Marketing Group Expands Client Services Team 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2
... largely unseen battle now raging in the workplace. It pits ... managers who covet the traditional employment deal money, career ... to playing the organizational game by traditional rules, e.g., long ... willingness to do whatever the business requires. Only Type A's ...
... the flu capital of North America. , ,Don't take that ... Wisconsin has yet to become a hot spot for the spread ... one. However, it may be the place where a possible pandemic ... in the national mobilization against the virulent H5N1 strain of the ...
... Summers created a firestorm last year when he suggested that ... result of intrinsic aptitude differences between men and women. While ... is the former president of Harvard, it focused the spotlight ... , ,In Wisconsin, diversity in top IT positions has a ...
Cached Biology Technology:Who will win the battle to redefine the workplace? 2Who will win the battle to redefine the workplace? 3Who will win the battle to redefine the workplace? 4Who will win the battle to redefine the workplace? 5Wisconsin stands at the center of scientific efforts to avert flu epidemics 2Wisconsin stands at the center of scientific efforts to avert flu epidemics 3Diversity still an elusive goal in IT, other tech fields 2Diversity still an elusive goal in IT, other tech fields 3
(Date:6/30/2015)... , June 30, 2015 Genisphere ... company as CEO to help further develop Genisphere,s therapeutics ... of partnering experience, having spent much of the last ... Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. Tom ... on Technology and Biotech Corporate Finance. He graduated from ...
(Date:6/25/2015)... N.J. , June 25, 2015  TAKE Solutions ... a patent by the United States Patent and Trademark ... Standardization". This process leverages TAKE Solutions, Clinical Accelerators to ... over 50% (when compared to standardization without the accelerators), ... At the heart of ...
(Date:6/24/2015)... 24, 2015 Biometry authentication provider KeyLemon ... password solution one face in. ... one face in, entering the expanding biometric authentication ... multifactor-authentication biometric answer to the password problem. With ... partnership with KeyLemon, one face in allows users ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... vegetable oil or sweet syrup knows that neither oil nor ... both leave a nasty film of carbon on the cookware. ... flash volatilization process" that heats oil and sugar about a ... produces hydrogen and carbon monoxide, a mixture called synthesis gas, ...
... is accelerating and threatening human well-being, according to a ... journal Science published by AAAS, the nonprofit ... ecosystems and this trend has recently been accelerating," said ... some of the consequences. For example, if the long-term ...
... the first time why a feeling of control helps us ... Centre for Neuroimaging at UCL, London, has implications for how ... a debilitating condition. , Using fMRI scanners, which allow scientists ... Dr Katja Wiech and Dr Raffael Kalisch, showed that when ...
Cached Biology News:U of M researchers invent 'flashy' new process to turn soy oil, glucose into hydrogen 2By 2048 all current fish, seafood species projected to collapse 2By 2048 all current fish, seafood species projected to collapse 3Trying to control pain can be a double-edged sword, say scientists 2Trying to control pain can be a double-edged sword, say scientists 3
... ultimate in utility and flexibility press-to-seal silicone ... needs of the researcher. They are available ... as sheet material that can be easily ... are autoclavable and non-cytotoxic and can be ...
The ELISA Kit for Hepatitis B Surface Antigen (HBsAg) is an in vitro enzyme immunoassay for the detection of HBsAg in human serum or plasma....
Alexa Fluor 350/488/594 Filter Set (Semrock Brightline) *mounted* *Zeiss Axio AF...
...
Biology Products: